Barclays PLC Purchases 11,041 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

Barclays PLC increased its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 9.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 127,065 shares of the biotechnology company’s stock after purchasing an additional 11,041 shares during the period. Barclays PLC owned 0.26% of REGENXBIO worth $982,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of RGNX. Teacher Retirement System of Texas boosted its stake in shares of REGENXBIO by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 2,088 shares during the period. DnB Asset Management AS boosted its position in REGENXBIO by 20.1% during the fourth quarter. DnB Asset Management AS now owns 14,539 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 2,434 shares during the period. GAMMA Investing LLC increased its holdings in shares of REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares during the last quarter. Geode Capital Management LLC raised its position in shares of REGENXBIO by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company’s stock valued at $8,460,000 after purchasing an additional 5,574 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of REGENXBIO during the 4th quarter worth about $54,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Price Performance

REGENXBIO stock opened at $9.76 on Tuesday. The stock’s fifty day moving average price is $7.22 and its two-hundred day moving average price is $8.06. The firm has a market cap of $489.14 million, a PE ratio of -1.94 and a beta of 1.11. REGENXBIO Inc. has a one year low of $5.04 and a one year high of $17.35.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.26. The business had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. Sell-side analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RGNX has been the topic of a number of research reports. Chardan Capital reiterated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Thursday, March 20th. Morgan Stanley upped their target price on REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, March 14th. Leerink Partners set a $24.00 price target on REGENXBIO in a report on Tuesday, March 18th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Finally, HC Wainwright lowered their price objective on REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Monday, March 17th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, REGENXBIO presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.63.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.